STIM1 and B-cell chronic lymphocytic leukemia: Finally, the capacity of an anti-STIM1 mAb to block constitutive Ca2+ entry and to reduce in vitro CLL cell viability, when associated with Rituximab, was reported within the high STIM1PM CLL subgroup.